For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Cytokinetics, Inc.

USPTO Granted Patents = 257

CIPO Patents = 7

EPO Patents = 34

Trademarks = 5

Forward Citations = 2,505

Loading Chart...

Loading Chart...

202 inventors (with patents filed for the assignee):

Bradley Paul Morgan (92 out of 101 patents)

David John Morgans, Jr (72 out of 100 patents)

Christophe Beraud (65 out of 66 patents)

4. Gustave Bergnes (58 out of 63 patents)

5. Pu-Ping Lu (57 out of 58 patents)

6. Richard Freedman (44 out of 44 patents)

7. Alex R Muci (43 out of 44 patents)

8. Xiangping Qian (42 out of 92 patents)

9. Fady Malik (36 out of 36 patents)

10. Jeffrey T Finer (34 out of 35 patents)

11. Luke W Ashcraft (32 out of 32 patents)

12. Chihyuan Chuang (31 out of 36 patents)

13. Erica Anne Kraynack (30 out of 31 patents)

14. Roman Sakowicz (30 out of 39 patents)

15. Scott E Collibee (26 out of 26 patents)

Core Competencies:

Cardiac Sarcomere Activators

Hypertrophic Cardiomyopathy

Heart Failure Treatments

Bicyclic Diazepanones

Heterocyclic Compounds

Aficamten Preparation

Omecamtiv Mecarbil

Skeletal Muscle Modulators

Bisamide Compounds

Tetrahydroisoquinoline Derivatives

Pharmaceutical Compositions

Combination ALS Therapy

257 patents: Sort by Forward Citations

1. 12441691 - Bicyclic 1,4-diazepanones and therapeutic uses thereof (2025-10-14),

2. 12370179 - Methods for treating hypertrophic cardiomyopathy (2025-07-29),

3. 12295952 - Methods of treating heart failure with cardiac sarcomere activators (2025-05-13),

4. 12286437 - Cardiac sarcomere inhibitors (2025-04-29),

5. 12275741 - Cardiac sarcomere inhibitors (2025-04-14),

6. 12275704 - Heterocyclic compounds and their uses (2025-04-14),

7. 12264133 - Compounds, compositions and methods (2025-04-01),

8. 12247024 - Process for preparing aficamten (2025-03-11),

9. 12221417 - Salt of omecamtiv mecarbil and process for preparing salt (2025-02-11),

10. 12194039 - Methods of treating heart failure by administering omecamtiv mecarbil (2025-01-14),

11. 12187712 - Cardiac sarcomere inhibitors (2025-01-07),

12. 12187700 - Polymorphs and cocrystals of a cardiac troponin activator (2025-01-07),

13. 12065436 - Cardiac sarcomere inhibitors (2024-08-20),

14. 11986474 - Methods for treating heart failure by administering cardiac sarcomere activators (2024-05-21),

15. 11981644 - Bicyclic 1,4-diazepanones and therapeutic uses thereof (2024-05-14),

Cytokinetics, Inc. is a biopharmaceutical company that develops muscle biology-driven treatments for debilitating diseases. Their research and development efforts focus on cardiac and skeletal muscle activators to address diseases such as heart failure, ALS, and spinal muscular atrophy. They strive to improve patients' lives by developing innovative therapies that enhance muscle function and overall wellbeing.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

257 Patents

#7 in South San Francisco, CA

#356 in California

#1,609 in US

#3,291 in the World

South San Francisco, CA, United States of America

Cytokinetics, Inc.

Forward Citations = 2,505

202 inventors:

Bradley Paul Morgan (92 out of 101 patents)

David John Morgans, Jr (72 out of 100 patents)

Christophe Beraud (65 out of 66 patents)

4. Gustave Bergnes (58 out of 63 patents)

5. Pu-Ping Lu (57 out of 58 patents)

Please report any incorrect information to support@idiyas.com

Loading…